Immix Biopharma

IMMX · NASDAQ

$8.91+$0.69 (+8.39%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $8.22

IMMX analyst rating

BuyConsensus of 8 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy8
Hold0
Underperform0
Sell0

12-month price target · 10 analysts

Average $25.04 (+181.0% upside)

Low: $17.57
Now: $8.91
High: $31.50

Upgrades and downgrades

The latest rating actions, newest first

IMMX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Needham	Sep 29, 2026	Maintains	Buy	$21.00 → $30.00	38%
Mizuho	Sep 15, 2026	Maintains	Outperform	$15.00 → $26.00	54%
Morgan Stanley	Aug 11, 2026	Maintains	Overweight	$20.00 → $19.00	57%
HC Wainwright & Co.	Aug 10, 2026	Maintains	Buy	$20.00 → $25.00	41%
Needham	Jul 22, 2026	Initiates	Buy	$21.00	38%
B of A Securities	Jun 18, 2026	Initiates	Buy	$27.00	45%
LifeSci Capital	Jun 17, 2026	Initiates	Outperform	$19.00	—
HC Wainwright & Co.	May 22, 2026	Maintains	Buy	$15.00 → $20.00	41%
HC Wainwright & Co.	Mar 30, 2026	Maintains	Buy	$15.00	41%
Mizuho	Mar 30, 2026	Maintains	Outperform	$14.00 → $15.00	54%

The case for and against

Updated Oct 14, 2026

Bull case

Immix Biopharma is positioned favorably because NXC-201 has shown unusually strong clinical efficacy in a high-unmet-need rare disease, with an 89% complete response rate across 45 patients, 100% cardiac response, 92% organ response, and no relapses reported as of the data cut-off. Its safety profile also appears differentiated, with no grade ≥3 CRS, no grade ≥3 infections, or any ICANS observed, which is especially important in frail AL amyloidosis patients where existing off-label options deliver only ~30-40% CR rates. Commercially, the company is preparing for launch by targeting ~60-70 FACT-accredited centers and ~2,800 hematology/oncology prescribers, while its ~$234.2M cash balance and runway into mid-2027 support development through planned updates in 1H:27 and a potential filing in 2027.

Bear case

Immix Biopharma is challenged by binary clinical risk around NXC-201, where safety concerns such as CRS and ICANS could undermine its tolerability and delay filing plans, while no program has FDA approval. Its lead CAR-T also faces intensifying competition from TCEs and other CAR-Ts that have shown strong response rates, and the company’s own data must still prove durable enough in a more heavily treated population. Financially, as a development-stage biotech with commercial-trial ambitions, it may need additional funding and could face unfavorable financing, reimbursement, and manufacturing constraints.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.